These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 4723260)

  • 1. Diphenylhydantoin side effects and serum albumin levels.
    Clin Pharmacol Ther; 1973; 14(4):529-32. PubMed ID: 4723260
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum folate levels during anticonvulsant therapy with diphenylhydantoin.
    Haghshenass M; Rao DB
    J Am Geriatr Soc; 1973 Jun; 21(6):275-7. PubMed ID: 4710646
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma albumin concentration and binding of diphenylhydantoin in man.
    Porter RJ; Layzer RB
    Trans Am Neurol Assoc; 1974; 99():45-9. PubMed ID: 4463562
    [No Abstract]   [Full Text] [Related]  

  • 4. Diphenylhydantoin dosage.
    Eadie MJ; Tyrer JH; Hooper WD
    Proc Aust Assoc Neurol; 1973; 10(0):53-9. PubMed ID: 4792162
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: Plasma diphenylhydantoin levels.
    Ourrier RA
    Aust N Z J Med; 1974 Oct; 4(5):524-6. PubMed ID: 4532924
    [No Abstract]   [Full Text] [Related]  

  • 6. [Difference of serum diphenylhydantoin levels between cases taking diphenylhydantoin alone and cases taking multiple anti-convulsants in various age groups (author's transl)].
    Takamatsu N
    No To Shinkei; 1979 Jun; 31(6):561-8. PubMed ID: 465197
    [No Abstract]   [Full Text] [Related]  

  • 7. The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children.
    ter Heine R; van Maarseveen EM; van der Westerlaken MM; Braun KP; Koudijs SM; Berg MJ; Malingré MM
    J Child Neurol; 2014 Jun; 29(6):803-10. PubMed ID: 23670246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.
    Johnson GJ; Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
    Br J Clin Pharmacol; 1989 Jun; 27(6):843-9. PubMed ID: 2503019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease.
    Hooper WD; Bochner F; Eadie MJ; Tyrer JH
    Clin Pharmacol Ther; 1974 Mar; 15(3):276-82. PubMed ID: 4815953
    [No Abstract]   [Full Text] [Related]  

  • 10. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury.
    Markowsky SJ; Skaar DJ; Christie JM; Eyer SD; Ehresman DJ
    Ann Pharmacother; 1996 May; 30(5):443-8. PubMed ID: 8740320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and risks of diphenylhydantoin in cardiac arrhythmias].
    Reimann R; Lemmel W; Theisen K
    Munch Med Wochenschr; 1971 Jun; 113(23):893-9. PubMed ID: 4103259
    [No Abstract]   [Full Text] [Related]  

  • 12. The gingival hyperplasia resulting from diphenylhydantoin in children and adults.
    Matsumoto K; Nakagawa K; Kaneko Z
    Int J Clin Pharmacol Biopharm; 1975 Oct; 12(3):369-71. PubMed ID: 1176242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphenylhydantoin-induced asterixis. A clinical study.
    Murphy MJ; Goldstein MN
    JAMA; 1974 Jul; 229(5):538-40. PubMed ID: 4406897
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects.
    Buchthal F; Svensmark O
    Psychiatr Neurol Neurochir; 1971; 74(2):117-36. PubMed ID: 5004709
    [No Abstract]   [Full Text] [Related]  

  • 15. Phenytoin in rheumatoid arthritis.
    Grindulis KA; Nichol FE; Oldham R
    J Rheumatol; 1986 Dec; 13(6):1035-9. PubMed ID: 3560089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma diphenylhydantoin levels after loading and maintenance doses.
    Wilder BJ; Serrano EE; Ramsay RE
    Clin Pharmacol Ther; 1973; 14(5):797-801. PubMed ID: 4729898
    [No Abstract]   [Full Text] [Related]  

  • 17. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphenylhydantoin-induced hepatitis.
    Ting S; Dunsky EH
    Ann Allergy; 1982 Jun; 48(6):331-2. PubMed ID: 6212004
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: Question on diphenylhydantoin dosage.
    Schwartz IL
    Pediatrics; 1975 Jun; 55(6):897. PubMed ID: 1134895
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of diphenylhydantoin on glaucomatous field loss: a preliminary report.
    Becker B; Stamper RL; Asseff C; Podos SM
    Trans Am Acad Ophthalmol Otolaryngol; 1972; 76(2):412-22. PubMed ID: 4270306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.